Comparative Pharmacology
Head-to-head clinical analysis: GYNAZOLE 1 versus NIZORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GYNAZOLE 1 versus NIZORAL.
GYNAZOLE-1 vs NIZORAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Butoconazole nitrate, an imidazole antifungal agent, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing fungal cell membrane permeability.
Inhibits fungal CYP51 (lanosterol 14α-demethylase), blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
One 100 mg vaginal ovule inserted intravaginally as a single dose.
Ketoconazole 200 mg orally once daily with food. For severe infections, increase to 400 mg once daily. Duration depends on indication.
None Documented
None Documented
Terminal elimination half-life is approximately 6-7 days after intravaginal administration, reflecting slow absorption from the vaginal mucosa and prolonged retention in tissues.
Biphasic elimination: initial half-life ~2 hours, terminal half-life 6–10 hours in adults with normal hepatic function; prolonged in hepatic impairment.
Primarily as unchanged drug in feces via biliary elimination; <1% excreted renally as metabolites.
Approximately 70% of the dose is excreted unchanged in feces via biliary elimination, and about 20–35% is excreted in urine, with less than 1% as unchanged drug in urine.
Category C
Category C
Azole Antifungal
Azole Antifungal